Thursday, October 01, 2026

by Adam Irvine, Physicians Office Resource 

Few office encounters appear more straightforward than a child with a sore throat. A parent reports that strep is circulating at school, the tonsils look inflamed, and the family wants an answer before leaving. Yet this common presentation requires several decisions: Is testing indicated? Which test is most appropriate? How much confidence should be placed in the result? Does a detected organism represent infection or carriage? And how can the plan be explained without making the family feel that a test or antibiotic is being withheld?

The modern physician office has more diagnostic options than ever. Traditional rapid antigen detection tests remain inexpensive and familiar. Throat culture is still an important reference method. Rapid nucleic acid amplification tests can provide molecular-level sensitivity during the visit. Each option offers advantages, but no technology eliminates the need for clinical judgment. 

For physicians, the goal is not simply to find group A Streptococcus (GAS). It is to identify the patients whose symptoms are caused by GAS, treat confirmed disease appropriately, and avoid turning colonization or viral illness into an antibiotic prescription. 

Testing begins with pretest probability

Viruses cause most episodes of acute pharyngitis. GAS accounts for approximately 20% to 30% of pharyngitis in children and 5% to 15% in adults. It occurs most often among children ages 5 through 15 and is uncommon in children younger than 3.¹ 

Typical GAS features include sudden-onset sore throat, fever, painful swallowing, tender anterior cervical lymphadenopathy, palatal petechiae, tonsillar erythema, and tonsillar enlargement or exudate. Cough, rhinorrhea, hoarseness, oral ulcers, and conjunctivitis favor a viral diagnosis. When clear viral features are present, CDC guidance indicates that GAS testing is unnecessary.¹ 

When viral features are absent, physical examination alone cannot reliably separate GAS from viral pharyngitis. This is where testing becomes valuable—but testing should still be selective. The 2025 Infectious Diseases Society of America (IDSA) guideline update suggests using a clinical scoring system to determine who should be tested. Centor, McIsaac, and similar tools are most useful for identifying low-probability patients in whom testing is unlikely to change care.² 

A score is a decision aid, not a diagnosis. It should be considered alongside age, local epidemiology, household exposure, previous rheumatic fever, immune status, and signs of complicated infection. Patients with scarlet fever, a suspected deep-neck infection, or systemic toxicity require evaluation beyond a routine sore-throat pathway. 

Routine testing is generally not recommended in children younger than 3 because classic GAS pharyngitis and acute rheumatic fever are rare in that age group. Selective testing may be appropriate when risk is increased, such as symptomatic illness in a young child with a school-aged sibling who has documented GAS infection. 

Rapid antigen detection tests: practical, fast, and familiar

Rapid antigen detection tests (RADTs) identify GAS carbohydrate antigen from a throat swab. Most produce a result within minutes, allowing the clinician to make a treatment decision during the encounter. They are widely available, relatively inexpensive, and commonly categorized as CLIA-waived for point-of-care use. 

The principal strength of RADTs is specificity. A positive result in a symptomatic, appropriately selected patient is generally considered sufficient confirmation of GAS pharyngitis. The main limitation is sensitivity, which varies among products and across clinical settings. A large systematic review in children reported an average RADT sensitivity of approximately 86% and specificity of approximately 95% when compared with throat culture.³ Put another way, antigen testing can miss a meaningful minority of culture-positive infections even though false-positive analytic results are uncommon. 

Performance is not determined by the kit alone. Organism burden, timing of illness, adequacy of the specimen, adherence to the manufacturer’s instructions, and the quality of the comparator culture can all influence apparent accuracy. A rushed or superficial swab may produce a false-negative result regardless of the assay’s performance in a regulatory study. 

For symptomatic children age 3 or older, CDC recommends confirming a negative RADT with throat culture. The practice should have a defined system for tracking the culture, contacting the family, and prescribing an antibiotic if it becomes positive. Routine backup culture after a negative RADT is not generally recommended for adults because GAS prevalence and the risk of acute rheumatic fever are lower.¹ 

Rapid molecular tests: higher sensitivity at the point of care

Nucleic acid amplification tests (NAATs) detect genetic material from GAS using methods such as polymerase chain reaction or isothermal amplification. Some platforms provide results in 15 to 30 minutes, making true molecular testing feasible during an office visit. 

Rapid NAATs generally offer greater sensitivity than antigen tests. A 2021 systematic review and meta-analysis reported pooled sensitivity of 97.5% and specificity of 95.1% compared with throat culture.⁴ Their high negative agreement means that, for many FDA-cleared molecular assays, a negative result can be used without a backup culture. Practices must follow the instructions for the specific platform and applicable clinical guidance; “molecular” is a category, not a guarantee that every test has identical performance or follow-up requirements. 

NAATs can improve workflow by reducing callbacks, delayed prescriptions, and loss to follow-up. They may be particularly valuable in high-volume pediatric, urgent care, or family medicine settings where completing backup cultures is operationally difficult. Potential disadvantages include higher instrument and per-test costs, maintenance or connectivity requirements, and the need to redesign workflow around assay run time. 

There is also a clinical tradeoff. High analytic sensitivity may increase detection of low-level GAS in carriers. A molecular test can establish that GAS nucleic acid is present, but it cannot independently prove that GAS is causing the sore throat. Patient selection remains essential. 

Throat culture: slower, but still clinically important

Throat culture has traditionally been regarded as the diagnostic reference standard. The sample is inoculated onto appropriate media and observed for GAS growth, typically requiring 24 to 48 hours. Culture may detect infections missed by less-sensitive antigen tests and allows laboratories to characterize isolates when clinically or epidemiologically necessary. 

Its weaknesses are familiar: delayed results, laboratory handling requirements, and the possibility that families cannot be reached after the visit. Culture performance also varies with specimen quality, transport, incubation, media, and laboratory technique. Although often described as a gold standard, culture is not infallible. 

Culture remains especially useful as a backup after a negative antigen test in children, when a rapid molecular platform is unavailable, or when the diagnosis remains important but an immediate answer is not required. Its value depends on a closed-loop result process. A culture ordered without reliable review and family notification is not a completed diagnostic strategy. 

Accuracy is more than sensitivity and specificity

Sensitivity and specificity describe test performance under defined conditions, but positive and negative predictive values change with disease prevalence. During peak GAS season in a school-aged population with compatible symptoms, a positive result is more likely to represent true disease. In a patient with cough, rhinorrhea, and a low pretest probability, the same positive result is more likely to be clinically misleading. 

This is the practical consequence of indiscriminate testing: even a highly specific assay produces less useful positive results when applied to low-risk patients. The question is not only whether the test correctly detected GAS. It is whether GAS explains the illness. 

Asymptomatic pharyngeal carriage makes that distinction difficult. A carrier who develops a viral upper respiratory infection may test positive by antigen, culture, or NAAT. The clinician may then attribute viral symptoms to strep and prescribe an antibiotic that offers no benefit. More sensitive testing does not remove this problem and may make it more visible. 

Recurrent “strep” should prompt a review of the pattern. Were prior episodes accompanied by classic GAS features? Were tests obtained during obvious viral illnesses? Was there a clinical response consistent with the expected course? Could there be repeated exposure, incomplete adherence, or a carrier state? Routine testing of asymptomatic patients, household contacts, or patients after treatment is generally unnecessary except in selected circumstances.⁵ 

The swab is part of the test

All three diagnostic methods depend on adequate specimen collection. The swab should contact both tonsillar pillars or fossae and the posterior pharynx while avoiding the tongue, teeth, and buccal mucosa. Good lighting, proper positioning, and a deliberate technique matter. 

Preparing the child can improve collection. A brief explanation—“This will touch the back of your throat, it may make you gag, and it will be over quickly”—is often better than surprising the patient. If the collector is confident that the intended anatomy was not sampled, repeating the swab may be more appropriate than accepting a questionable negative result. 

Point-of-care quality systems also influence accuracy. Practices should follow storage requirements, expiration dates, control procedures, timing windows, and result-interpretation instructions. Staff need initial training and ongoing competency assessment. CLIA-waived does not mean error-proof; it means the test is simple and carries a low risk of erroneous results when performed as directed. 

Matching the testing strategy to the practice

There is no single best platform for every physician office. A practice should consider its population, visit volume, staffing, laboratory certificate, follow-up reliability, available space, reimbursement environment, and total cost—not merely the purchase price of a test. 

An antigen-first strategy may be appropriate when speed and affordability are priorities and the practice can reliably culture negative pediatric specimens. A molecular-first strategy may be attractive when a definitive same-visit answer is worth the added expense or when backup-culture workflows are unreliable. Culture-first testing may remain reasonable when rapid turnaround is unnecessary and laboratory access is dependable. 

Before adopting a platform, clinicians should review the FDA-cleared intended use and independent performance evidence. Questions should include: What are the sensitivity and specificity in the intended age group? Is the comparator an optimized culture? Does a negative result require confirmation? What is the invalid-result rate? How long is hands-on time compared with total run time? Can the result interface with the EHR? What quality-control and maintenance procedures are required? 

Practices should periodically audit their pathway. Useful measures include the percentage of sore-throat visits tested, positivity rates by age group, completion of indicated backup cultures, antibiotic prescribing after negative tests, invalid-test frequency, and time from positive culture to family notification. Unexpectedly low positivity may suggest over testing; unexpectedly high positivity can reflect appropriate selection, an outbreak, or testing of carriers and deserves context. 

Managing parent expectations before the result

Parents often ask for a test because they want certainty, symptom relief, protection for siblings, or documentation for school. Addressing that concern directly is more effective than simply saying that a swab is unnecessary. 

A practical conversation can follow four steps: acknowledge the concern, explain the probability, recommend a plan, and provide a safety net. 

For a child with clear viral features, the clinician might say: “I understand why you’re worried about strep, especially if it is going around. The cough and runny nose point strongly toward a virus. Testing now could find strep bacteria your child is carrying even if those bacteria are not causing this illness, which could lead us to use an antibiotic that will not help.” 

When testing is appropriate, explain the pathway before swabbing: “This rapid test is very good at confirming strep when it is positive. If it is negative, we will send a culture because rapid antigen tests can miss some infections in children. We will call you and start treatment if the culture is positive.” For a molecular test, explain that the method is sensitive enough that a negative result generally ends the strep evaluation, assuming that is consistent with the specific assay’s instructions. 

If the result is negative, avoid presenting the encounter as a dead end. Offer a positive treatment plan: weight- and age-appropriate analgesics or antipyretics, hydration, soothing liquids, and other appropriate comfort measures. Explain the expected course and provide clear reasons to return, including breathing difficulty, drooling or inability to swallow, dehydration, neck swelling or stiffness, trismus, muffled voice, toxic appearance, new rash, persistent fever, or worsening symptoms. 

When a parent expects antibiotics, concise language can preserve trust: “The negative result tells us that an antibiotic is unlikely to help. Antibiotics can cause diarrhea, rash, allergic reactions, and other problems, so the safest treatment is symptom relief and close observation. If the culture changes the answer, we will contact you.” 

For confirmed GAS, set realistic expectations. Antibiotics shorten illness modestly, reduce transmission, and lower the risk of complications; they do not necessarily produce immediate relief. Penicillin or amoxicillin remains first-line therapy for patients without an allergy. Patients should be afebrile and have received appropriate antibiotics for at least 12 to 24 hours before returning to school or daycare, consistent with CDC guidance.¹ 

Better technology, better conversations

The expanding menu of strep tests gives physician offices meaningful choices. RADTs provide rapid, specific, affordable results but can miss infections. NAATs offer higher sensitivity and often eliminate backup culture, though at greater cost and with continued risk of detecting carriage. Culture remains valuable but requires time and a dependable follow-up system. 

The best test is therefore not simply the assay with the highest sensitivity. It is the test that fits the patient’s pretest probability, the practice’s workflow, and a clear management plan. Used selectively, collected correctly, and interpreted in context, strep testing can support both diagnostic accuracy and antibiotic stewardship. 

Parents are more likely to accept that approach when clinicians explain not only what they are doing, but why. A well-managed encounter leaves the family with an answer when possible, a plan in every case, and confidence that avoiding an unnecessary test or antibiotic is an act of careful medicine—not inaction. 

References

Centers for Disease Control and Prevention. Clinical guidance for group A streptococcal pharyngitis. Updated November 18, 2025. Accessed September 10, 2026. https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/strep-throat.html 

Linder JA, Barshak MB, Wessels MR, et al. 2025 clinical practice guideline update by the Infectious Diseases Society of America on group A streptococcal pharyngitis: risk assessment using clinical scoring systems in children and adults. Clin Infect Dis. Published online November 26, 2025. doi:10.1093/cid/ciaf668 

Cohen JF, Bertille N, Cohen R, Chalumeau M. Rapid antigen detection test for group A streptococcus in children with pharyngitis. Cochrane Database Syst Rev. 2016;7(7). doi:10.1002/14651858.CD010502.pub2 

Dubois C, Smeesters PR, Refes Y, Levy C, Bidet P, Cohen R. Diagnostic accuracy of rapid nucleic acid tests for group A streptococcal pharyngitis: systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(12):1736-1745. doi:10.1016/j.cmi.2021.04.021 

Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10). doi:10.1093/cid/cis629